Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimatoprost SR Duration in Glaucoma or Ocular Hypertension
NCT03850782Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2019
- Primary completion
- Aug 2025
- Modality
- Orthosteric Ligands
- Countries
- 16
01
Overview
Phase 3, open-label trial of bimatoprost in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by AbbVie Inc. Primary endpoints: Time to Retreatment or Rescue Administered for IOP at 48 months and Number of Patients Experiencing a Treatment Emergent Adverse Event at 48 months. Started Feb 2019; status: completed.
02
Drugs
bimatoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT03850782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03850782.